Experimental drug for Sjögren's disease symptoms
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests an experimental medication called ONO-4915 for people with primary Sjögren's disease. It aims to see if the drug can reduce dryness and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 74 years old.
- You must have been diagnosed with primary Sjögren's disease within the last 10 years.
- You must test positive for the anti-SSA/Ro antibody in your blood.
- You must have a certain level of dryness and symptoms (score of at least 5 on a standard scale).
- You must not have any other autoimmune diseases.
- You must be currently free of active infections and have no recent history of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
This study tests a new medicine called ESG206, which is designed to calm the immune system and reduce the symptoms of Sjögren's syndrome. If you join, you may get this medicine or a placebo, and the study will see if it safely helps with things like dry eyes and dry mouth.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This trial tests an investigational drug called IBI355 for people with moderate-to-severe Sjögren's disease. It aims to reduce inflammation and improve symptoms by targeting part of the immune system.
Hear when a new Sjogrens Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.